» Articles » PMID: 11375420

CD8(+) Lymphocytes Respond to Different HIV Epitopes in Seronegative and Infected Subjects

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2001 May 26
PMID 11375420
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

HIV-1-specific cytotoxic T-lymphocyte (CTL) responses have been detected at a low frequency in many HIV-1-exposed, persistently seronegative (HEPS) subjects. However, it is unclear how CTLs could protect against HIV acquisition in HEPS subjects, when high levels of circulating CTL fail to prevent disease progression in most seropositive subjects. To address this issue we studied CD8(+) lymphocyte responses to a panel of HIV-1 CTL epitopes in 91 HEPS and 87 HIV-1-infected Nairobi sex workers. HIV-specific responses in seropositive women focused strongly on epitopes rarely or never recognized in HEPS subjects, who targeted epitopes that were subdominant or unrecognized in infected women. These differences in epitope specificity were restricted by only those HLA class I alleles that are associated with a reduced risk of HIV-1 infection in this cohort. Late seroconversion in HEPS donors was associated with a switch in epitope specificity and/or immunodominance to those epitopes preferentially recognized by HIV-1-infected women. The likelihood of detecting HIV-1-specific responses in HEPS women increased with the duration of viral exposure, suggesting that HIV-1-specific CD8(+) responses are acquired over time. The association between differential recognition of distinct CTL epitopes and protection from HIV-1 infection may have significant implications for vaccine design.

Citing Articles

Making a Monkey out of Human Immunodeficiency Virus/Simian Immunodeficiency Virus Pathogenesis: Immune Cell Depletion Experiments as a Tool to Understand the Immune Correlates of Protection and Pathogenicity in HIV Infection.

Symmonds J, Gaufin T, Xu C, Raehtz K, Ribeiro R, Pandrea I Viruses. 2024; 16(6.

PMID: 38932264 PMC: 11209256. DOI: 10.3390/v16060972.


HIV-1 protective epitope-specific CD8 T cells in HIV-1-exposed seronegative individuals.

Chikata T, Gatanaga H, Nguyen H, Mizushima D, Zhang Y, Kuse N iScience. 2023; 26(11):108089.

PMID: 37867946 PMC: 10589889. DOI: 10.1016/j.isci.2023.108089.


Can T Cells Abort SARS-CoV-2 and Other Viral Infections?.

Swadling L, Maini M Int J Mol Sci. 2023; 24(5).

PMID: 36901802 PMC: 10002440. DOI: 10.3390/ijms24054371.


Natural Immunity against HIV-1: Progression of Understanding after Association Studies.

Luo M Viruses. 2022; 14(6).

PMID: 35746714 PMC: 9227919. DOI: 10.3390/v14061243.


The CD8 T Cell Noncytotoxic Antiviral Responses.

Morvan M, Teque F, Locher C, Levy J Microbiol Mol Biol Rev. 2021; 85(2).

PMID: 33980586 PMC: 8139528. DOI: 10.1128/MMBR.00155-20.


References
1.
Tsomides T, Aldovini A, Johnson R, Walker B, Young R, Eisen H . Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J Exp Med. 1994; 180(4):1283-93. PMC: 2191672. DOI: 10.1084/jem.180.4.1283. View

2.
Borrow P, Lewicki H, Hahn B, Shaw G, Oldstone M . Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994; 68(9):6103-10. PMC: 237022. DOI: 10.1128/JVI.68.9.6103-6110.1994. View

3.
Haynes B, Pantaleo G, Fauci A . Toward an understanding of the correlates of protective immunity to HIV infection. Science. 1996; 271(5247):324-8. DOI: 10.1126/science.271.5247.324. View

4.
Clerici M, Shearer G . Correlates of protection in HIV infection and the progression of HIV infection to AIDS. Immunol Lett. 1996; 51(1-2):69-73. DOI: 10.1016/0165-2478(96)02557-6. View

5.
Bunce M, ONeill C, Barnardo M, Krausa P, Browning M, Morris P . Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens. 1995; 46(5):355-67. DOI: 10.1111/j.1399-0039.1995.tb03127.x. View